A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III

DOI10.1111/BIOM.12994zbMath1436.62520OpenAlexW2898451045WikidataQ58112811 ScholiaQ58112811MaRDI QIDQ5214489

Andrew G. Chapple, Peter F. Thall

Publication date: 7 February 2020

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc6486466

zbMATH Keywords

clinical trialBayesian designdose findingphase I-II clinical trialphase III clinical trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Statistical block designs (62K10)

This page was built for publication: A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III